The current status and problems confronted in delivering precision medicine in Japan and Europe
- 21 February 2017
- journal article
- review article
- Published by Elsevier BV in Current Problems in Cancer
- Vol. 41 (3), 166-175
- https://doi.org/10.1016/j.currproblcancer.2017.02.003
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examplesAnnals of Oncology, 2017
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trialThe Lancet Respiratory Medicine, 2016
- Consensus on precision medicine for metastatic cancers: a report from the MAP conferenceAnnals of Oncology, 2016
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialAnnals of Oncology, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid TumorsNeoplasia, 2015
- A New Initiative on Precision MedicineThe New England Journal of Medicine, 2015
- Precision Medicine in Europe – Forging a Common VisionEuropean Oncology & Haematology, 2015
- Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)Annals of Oncology, 2014